Year |
Citation |
Score |
2015 |
Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26528901 DOI: 10.1016/J.Jconrel.2015.10.053 |
0.635 |
|
2015 |
Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 199: 72-83. PMID 25497312 DOI: 10.1016/J.Jconrel.2014.11.031 |
0.654 |
|
2014 |
Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Investigational New Drugs. 32: 1071-82. PMID 25064374 DOI: 10.1007/s10637-014-0138-x |
0.529 |
|
2014 |
Steino A, Bacha J, Garner WJ, Kanekal S, Waterhouse D, Santos ND, Brown DM. Abstract 824: In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer Cancer Research. 74: 824-824. DOI: 10.1158/1538-7445.Am2014-824 |
0.468 |
|
2013 |
Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. Plos One. 8: e62349. PMID 23626804 DOI: 10.1371/journal.pone.0062349 |
0.522 |
|
2013 |
Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Investigational New Drugs. 31: 46-58. PMID 22615060 DOI: 10.1007/s10637-012-9832-8 |
0.633 |
|
2012 |
Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB. Irinophore Câ„¢, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. Journal of Controlled Release : Official Journal of the Controlled Release Society. 158: 34-43. PMID 22001870 DOI: 10.1016/J.Jconrel.2011.09.095 |
0.653 |
|
2012 |
Wong MQ, Karim T, Yung A, Kozlowski P, Waterhouse D, Bally MB, Owen DA, Gill S, Tai IT, Ng SS, Yapp DT. Abstract 5261: Irinophore C, a liposomal formulation of irinotecan, has anti-vascular effects in primary tumors of colorectal cancer grown orthotopically in mice Cancer Research. 72: 5261-5261. DOI: 10.1158/1538-7445.Am2012-5261 |
0.517 |
|
2011 |
Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (London, England). 6: 1645-54. PMID 22077466 DOI: 10.2217/Nnm.11.140 |
0.657 |
|
2011 |
Ho VW, Leung K, Hsu A, Luk B, Lai J, Shen SY, Minchinton AI, Waterhouse D, Bally MB, Lin W, Nelson BH, Sly LM, Krystal G. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Research. 71: 4484-93. PMID 21673053 DOI: 10.1158/0008-5472.Can-10-3973 |
0.565 |
|
2011 |
Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. Bmc Cancer. 11: 124. PMID 21477311 DOI: 10.1186/1471-2407-11-124 |
0.673 |
|
2011 |
Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Research. 71: 3364-76. PMID 21415165 DOI: 10.1158/0008-5472.Can-10-4261 |
0.63 |
|
2011 |
Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strut D, Osooly M, Masin D, Bally MB. Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. Cancer Biology & Therapy. 11: 826-38. PMID 21358264 DOI: 10.4161/cbt.11.9.15183 |
0.657 |
|
2011 |
Patankar N, Anantha M, Ramsay E, Waterhouse D, Bally M. The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™. Pharmaceutical Research. 28: 848-57. PMID 21181548 DOI: 10.1007/S11095-010-0340-2 |
0.498 |
|
2011 |
Wong MQ, Karim T, Gill N, Waterhouse D, Bally MB, Owen DA, Tai IT, Ng SS, Yapp DT. Abstract B12: The effects of Irinophore C™ on the microenvironment and vasculature of a primary orthotopic model of colorectal cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B12 |
0.518 |
|
2010 |
Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Amankwa L, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. 144: 332-40. PMID 20202473 DOI: 10.1016/J.Jconrel.2010.02.029 |
0.645 |
|
2010 |
Lou Y, McDonald PC, Oloumi A, Chia S, Kyle A, Keller Uad, Fotovati A, Gray V, Leung S, Huntsman D, Clarke B, Waterhouse D, Bally M, Roskelley C, Overall C, et al. Abstract 455: Hypoxia induced carbonic anhydrase IX is essential for the growth and metastasis of breast tumors Cancer Research. 70: 455-455. DOI: 10.1158/1538-7445.Am10-455 |
0.616 |
|
2010 |
Neijzen RW, Wong M, Anantha M, Waterhouse D, Bally M, Ng SSW, Yapp DT. Abstract 3661: Vascular changes and potentiating secondary drug delivery in colorectal cancer with Irinophore C Cancer Research. 70: 3661-3661. DOI: 10.1158/1538-7445.Am10-3661 |
0.638 |
|
2009 |
Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Research : Bcr. 11: R25. PMID 19409087 DOI: 10.1186/Bcr2252 |
0.569 |
|
2008 |
de Lemos ML, Monfared S, Denyssevych T, Hamata L, Jennings S, Thiessen B, Smith S, Waterhouse D. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 15: 45-52. PMID 18772215 DOI: 10.1177/1078155208096902 |
0.345 |
|
2008 |
Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D, Bally MB. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1208-17. PMID 18281556 DOI: 10.1158/1078-0432.Ccr-07-0780 |
0.663 |
|
2008 |
Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Molecular Cancer Therapeutics. 7: 59-70. PMID 18202010 DOI: 10.1158/1535-7163.Mct-07-0329 |
0.629 |
|
2008 |
Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 68: 607-17. PMID 17904831 DOI: 10.1016/J.Ejpb.2007.08.011 |
0.532 |
|
2008 |
Winter JN, Waterhouse D, Ahn R, Chen H, Gordon LI, Jovanovic B, Bally M, O’Halloran T. Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies Blood. 112: 4989-4989. DOI: 10.1182/Blood.V112.11.4989.4989 |
0.629 |
|
2007 |
Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics. 6: 844-55. PMID 17339368 DOI: 10.1158/1535-7163.Mct-06-0159 |
0.538 |
|
2006 |
Waterhouse DN, Bally MB. Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. Nanomedicine (London, England). 1: 359-63. PMID 17716167 DOI: 10.2217/17435889.1.3.359 |
0.618 |
|
2006 |
Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharmaceutical Research. 23: 2575-85. PMID 17086505 DOI: 10.1007/PL00022054 |
0.613 |
|
2006 |
Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Zhang YZ, Yapp D, Dragowska W, Dunn S, et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Current Cancer Drug Targets. 6: 455-89. PMID 17017873 DOI: 10.2174/156800906778194586 |
0.643 |
|
2005 |
Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharmaceutical Research. 22: 915-22. PMID 15948035 DOI: 10.1007/S11095-005-4586-Z |
0.665 |
|
2005 |
Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. Journal of Controlled Release : Official Journal of the Controlled Release Society. 105: 89-105. PMID 15878792 DOI: 10.1016/J.Jconrel.2005.03.007 |
0.632 |
|
2005 |
Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods in Enzymology. 391: 71-97. PMID 15721375 DOI: 10.1016/S0076-6879(05)91004-5 |
0.669 |
|
2005 |
Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods in Enzymology. 391: 40-57. PMID 15721373 DOI: 10.1016/S0076-6879(05)91002-1 |
0.615 |
|
2004 |
Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Molecular Cancer Research : McR. 2: 606-19. PMID 15561777 |
0.577 |
|
2004 |
Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6638-49. PMID 15475454 DOI: 10.1158/1078-0432.Ccr-04-0221 |
0.581 |
|
2004 |
Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biology & Therapy. 3: 197-204. PMID 14726684 DOI: 10.4161/Cbt.3.2.622 |
0.648 |
|
2003 |
Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. Journal of Experimental Therapeutics & Oncology. 3: 261-71. PMID 14696623 DOI: 10.1111/j.1533-869X.2003.01099.x |
0.624 |
|
2002 |
Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. International Journal of Pharmaceutics. 241: 57-64. PMID 12086721 DOI: 10.1016/S0378-5173(02)00131-X |
0.52 |
|
2001 |
Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety. 24: 903-20. PMID 11735647 DOI: 10.2165/00002018-200124120-00004 |
0.587 |
|
2001 |
Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharmaceutical Research. 18: 1331-5. PMID 11683249 DOI: 10.1023/A:1013050330608 |
0.577 |
|
Show low-probability matches. |